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Implementation of Epilepsy Multigene
Panel Testing in Ontario, Canada
David A. Dyment†, Asuri N. Prasad †, Kym M. Boycott, Grace U. Ediae,
Taila Hartley, Ayman Hassan, Katherine E. Muir, Murray Potter, Lysa Boisse Lomax,
Olga Jarinova, Bekim Sadikovic, Dimitri J. Stavropoulos, O. Carter Snead III

ABSTRACT: Background: Epilepsy is a common neurological condition that shows a marked genetic predisposition. The advent of
next-generation sequencing (NGS) has transformed clinical genetic testing by allowing the rapid screen for causative variants in multiple
genes. There are currently no NGS-based multigene panel diagnostic tests available for epilepsy as a licensed clinical diagnostic test in
Ontario, Canada. Eligible patient samples are sent out of country for testing by commercial laboratories, which incurs signiﬁcant cost to
the public healthcare system. Objective: An expert Working Group of medical geneticists, pediatric neurologists/epileptologists,
biochemical geneticists, and clinical molecular geneticists from Ontario was formed by the Laboratories and Genetics Branch of the
Ontario Ministry of Health and Long-Term Care to develop a programmatic approach to implementing epilepsy panel testing as a
provincial service. Results: The Working Group made several recommendations for testing to support the clinical delivery of care in
Ontario. First, an extension of community healthcare outcomes-based program should be incorporated to inform and educate ordering
providers when requesting and interpreting a genetic panel test. Second, any gene panel testing must be “evidence-based” and takes into
account varied clinical indications to reduce the chance of uncertain and secondary results. Finally, an ongoing evaluative process was
recommended to ensure continued test improvement for the future. Conclusion: This epilepsy panel testing implementation plan will be a
model for genetic care directed toward a speciﬁc set of conditions in the province and serve as a prototype for genetic testing for other
genetically heterogeneous diseases.
RÉSUMÉ: Mise en œuvre d’un test diagnostique permettant en Ontario l’analyse d’un panel de plusieurs gènes liés à l’épilepsie. Contexte:
L’épilepsie demeure un trouble neurologique fréquent dont la prédisposition génétique apparaît notable. L’émergence du séquençage de nouvelle
génération (SNG) a aussi transformé les tests génétiques en permettant un dépistage rapide des variantes causales que l’on retrouve dans de nombreux
gènes. À l’heure actuelle, il n’existe pas, pour l’épilepsie, de tests diagnostiques homologués qui permettent en Ontario l’analyse d’un panel de gènes en
vertu du SNG. Les échantillons de patients admissibles sont alors envoyés à l’extérieur du Canada aﬁn d’être analysés par des laboratoires commerciaux,
ce qui pèse lourd dans les budgets des systèmes publics de santé. Objectif: Un groupe de travail formé d’experts (généticiens médicaux, neurologues
pédiatriques et spécialistes en épileptologie, généticiens biochimiques et généticiens moléculaires cliniques) a été formé par le service des laboratoires et
de la génétique des ministères de la Santé et des Soins de Longue durée de l’Ontario aﬁn d’élaborer une démarche programmatique visant à mettre en
œuvre des tests diagnostiques basés sur un panel de plusieurs gènes. Ces tests seraient ensuite reconnus à titre de service public. Résultats: En matière de
dépistage, ce groupe de travail a ainsi émis plusieurs recommandations visant à accompagner la prestation clinique en Ontario. Tout d’abord, un
programme s’inspirant du projet « ECHO » (Extension of Community Healthcare Outcomes) devrait être ajouté dans le but de renseigner et de
sensibiliser les prestataires de soins de santé qui demandent et qui interprètent ces tests basés sur un panel de plusieurs gènes. Ensuite, tout test de ce type
doit reposer sur des preuves et tenir compte d’une panoplie d’indications cliniques aﬁn de réduire les possibilités d’incertitude et de résultats secondaires.
Enﬁn, il a été recommandé de procéder à un processus continu d’évaluation pour s’assurer que ces tests puissent être améliorés dans le futur. Conclusion :
Ce plan de mise en œuvre de tests basés sur un panel de plusieurs gènes deviendra un modèle pour les soins destinés à un ensemble spéciﬁque de
problèmes de santé en Ontario. Outre l’épilepsie, il pourra servir comme prototype pour le dépistage d’autres maladies hétérogènes sur le plan génétique.
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INTRODUCTION
There are approximately 75,000 adults and 15,000 children
living with epilepsy in Ontario.1,2 The condition is clinically
heterogeneous and has diverse etiologies with age dependent
presentation.3 Twin and family studies show that epilepsy is a
highly heritable condition,4 and a proportion of affected individuals
will develop epilepsy due to pathogenic variant(s) in a single gene
(e.g., monogenic). These individually rare, highly penetrant disease-causing variants have previously been difﬁcult to diagnose by
molecular means until the advent of next-generation sequencing
(NGS). Several studies now show that NGS-based strategies can
provide a molecular diagnosis in 15%–30% of individuals with
epilepsy and, for speciﬁc clinical presentations, the rate can be
higher.4,5 As a result, the application of NGS has rapidly transformed the way in which genetic epilepsy is diagnosed. The
sequencing of dozens to even hundreds of genes is now possible
with a wide variety of “epilepsy panels” available through commercial laboratories.6 There are different panels available to the
clinician that include “targeted” panels, “comprehensive” panels
and panels generated by a “ﬁlter” for select genes. Generally, a
targeted panel has fewer genes than a comprehensive panel but
higher depth of coverage and complete overall coverage of the
target sequence, while the comprehensive panels may comprise
several hundred genes – typically with slightly less coverage of the
target sequence (97%–99%). A ﬁltered panel is a panel that includes
a subset of clinically relevant genes that are selected from a broad
gene capture and sequencing experiment (such as an exome). The
introduction of NGS testing into clinical care has subsequently
changed the knowledge requirements for physicians involved in the
care of persons with epilepsy. Physicians must now have a baseline
expertise in the ﬁeld of genetics; they must consider the potential
beneﬁt(s), harms, and limitations of pursuing genetic testing,
understand what type of genetic testing is most appropriate, may
be required to select the most suitable commercially available
genetic panel, inform and counsel patients and their families prior
to pursuing testing, and disseminate the results (whether positive,
negative, or uncertain) to others within the circle of care.4,7,8
The beneﬁts of a molecular diagnosis are signiﬁcant. An accurate
genetic diagnosis can direct treatment toward disease-modifying
therapies and/or medications known to be effective in certain
epilepsy syndromes. The information may also prevent the addition
of a potentially harmful medication. Genetic diagnosis can also
clarify the long-term prognosis and limit further diagnostic investigations that have associated risks and costs. A genetic diagnosis
may spare patients the morbidity, and society the costs, of invasive
and expensive evaluations for epilepsy surgery. Further, genetic
diagnoses often help to identify potential comorbidities allowing for
optimization of surveillance, early treatment, and associated reduction in disease morbidity. A genetic diagnosis will also provide
informed risks for genetic counseling purposes and provide prenatal
testing options. Finally, and importantly, a genetic diagnosis can
have a psychosocial beneﬁt to the individual and their families.
The Epilepsy Panels Implementation Working Group
Within Canada, each province and territory has its own
single-payer system of healthcare with differing, but similar,
clinical care delivery models. Ontario’s healthcare system is
funded by the Ministry of Health and Long-Term Care
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(MOHLTC) through the Ontario Health Insurance Plan (OHIP).
As previously described, genetic testing for epilepsy patients
living in Ontario has historical disparities in terms of who is
offered testing and what testing is conducted.9 This, in addition
to the known advantages of a molecular diagnosis for persons
with epilepsy, prompted the former Genetic Testing Advisory
Committee (GTAC; 2014–2017), established by the MOHLTC
for advice on the provision of genetic tests in Ontario,
to develop and disseminate the criteria for panel testing to
guide physicians caring for individuals with epilepsy in
Ontario9 (http://www.health.gov.on.ca/en/pro/programs/gtac/).
While this has aided clinicians in determining who should and
should not be tested, genetic testing for epilepsy continues to be
sent out of country (OOC) to several commercial laboratories
offering different epilepsy panels, creating inequity in patient
care at considerable cost to the MOHLTC, who funds testing
for eligible patients as an OHIP-funded service through the
Ministry’s Out-of-Country/Out-of-Province Prior Approval
Program for Laboratory and Diagnostic Services9 administered
by the Laboratories and Genetics Branch (LGB). Furthermore,
because this testing is conducted by a variety of commercial
laboratories with no requirements to report back to the
MOHLTC, there is little information as to whether Ontario
patients are beneﬁtting from this test in terms of a satisfactory
diagnostic yield or any other outcome measure of clinical utility.
As such, it was recognized that clinical testing within Ontario
could provide beneﬁts to patients, physicians, and the public
healthcare system, in terms of consistency, improved access, the
development of local expertise, and the generation of relevant
outcome data. Furthermore, locally performed genetic testing
has been shown to improve diagnostic yield.10 Given a need for
improved care, the Epilepsy Panels Implementation (EPI)
Working Group was formed by LGB with the purpose of
developing a programmatic approach to implementing epilepsy
panel testing in Ontario as a province-wide service.
The EPI Working Group members were identiﬁed for their
clinical expertise in the ﬁeld of epilepsy clinical care and their
experience in, and understanding of, the use of clinical genetic
testing in epilepsy in adults and children in the province of Ontario.
As well, the EPI Working Group members were selected to provide
widespread regional representation across the province of Ontario.
To fulﬁll the Working Group’s mandate, members were organized
into two subgroups – Clinical and Technical. The Clinical Group
was tasked with providing a testing algorithm to guide test utilization, develop performance indicators, and provide details for
resources and capacity. The Technical Group was focused on the
technical performance and service standards, as well as quality
assurance, ongoing evaluation processes and resources and capacity
as they relate to technical aspects of the test. The Clinical and
Technical Groups proceeded simultaneously via teleconference
meetings, and each was responsible for documenting their separate
discussions, developing the assigned content, and coordinating and
supporting each other to produce one cohesive ﬁnal report with
recommendations reﬂecting the consensus of the Working Group as
a whole. This process took place from July 2017 to February 2018.
Guiding Principles
Early in the process, the EPI Working Group highlighted
several key elements to include in the overall plan. The ﬁrst was
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Figure 1: Project ECHO Ontario – Epilepsy across the Hub-and-Spoke Organization. Represents
the hub-and-spoke model of ECHO. CHEO, Children’s Hospital of Eastern Ontario.

improved access and education to facilitate gene panel testing
throughout the province. At present, OOC testing is requested by
geneticists, metabolic specialists, and a few neurologists in
tertiary care centers. In order to inform and educate additional
care providers, epilepsy genetic testing was to be incorporated
into a video-conference-based extension of community healthcare outcomes (“ECHO”) model11 of knowledge translation for
epilepsy in Ontario. Secondly, it was recognized that genes
present on commercially available panels did not, necessarily,
show signiﬁcant scientiﬁc evidence of being clinically relevant to
epilepsy. Therefore, an evidence-based approach to the gene
composition of a panel, and the coverage of the genetic variation
within the gene, was considered a priority. Lastly, the test was to
be implemented as part of a sustainable program in order to
continually evaluate and improve epilepsy testing going forward.
Here, we present the recommendations generated by the EPI
Working Group to implement a comprehensive and unique
epilepsy genetic testing strategy for the province of Ontario.
Recommendations for the Implementation of an
Ontario-Based Epilepsy Genetic Test
Recommendation 1: An ECHO-Based Program Should Be
Incorporated to Inform and Educate Ordering Providers When
Requesting and Interpreting a Genetic Panel Test
Project ECHO is a program developed by Dr. Sanjeev Arora
in 2003 to help primary care providers in rural New Mexico
manage patients with hepatitis C.12 Project ECHO’s virtual
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hub-and-spoke educational model harnesses case-based learning
via video conferencing to facilitate primary care providers’
learning in conjunction with experts at academic health centers,
thus increasing the ability of participating primary care providers
to manage complex medical cases in their own practice. This
cadre of ECHO participants can then serve as an expert resource
for other providers in their community.
The ECHO model thus breaks down the walls between specialty
and primary care. It is designed to link expert specialist teams at an
academic “hub” with primary care providers in local communities –
the “spokes,” or community partners, of the model. Together, they
participate in weekly Tele-ECHO clinics, which are like virtual
grand rounds, combined with mentoring and patient case
presentations.
The Ontario Epilepsy Network has developed an ongoing
Project ECHO Ontario – Epilepsy Across the Life Span, in which
each District Epilepsy Centre and Regional Epilepsy Centre in
Ontario, as well as Thunder Bay, will serve as a hub that will recruit
primary care provider, pediatricians, and community neurology
spokes in their respective regions (https://oen.echoontario.ca/)
(Figure 1). The Project ECHO system is administered by The
Hospital for Sick Children and a common, accredited continuing
medical education (CME) curriculum is available for all hubs, one
in Epilepsy in Child and Youth and the other in Epilepsy in Adults.
The genetics of epilepsy will be incorporated into both curricula in
terms of pre- and postgenetic test counseling, as well as the
guidelines and indications for genetic testing in epilepsy. Project
ECHO’s relevance to genetic testing is through the insight gained
by “spokes,” including signiﬁcant knowledge that will enable

63

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

consistent and informed choices for genetic tests to be made
throughout the province for patients with epilepsy. These caregivers will serve as a local resource for epilepsy care in their
respective communities.
Recommendation 2: Develop and Implement Multiple
Evidence-Based Genetic Panel Tests Based on Speciﬁc Clinical
Indications for Epilepsy
A key element to the implementation of genetic diagnostic
testing for epilepsy in Ontario is that the genes selected have strong
supporting evidence for their role in epilepsy. This is in recognition
that many currently available epilepsy panels are comprised of
hundreds of genes, many of which may lack strong evidence for an
epilepsy association.6 In addition, the comprehensive panels
offered commercially may be comprised of genes with a heterogeneous mix of clinical indications (e.g., a panel may have genes
associated with storage and metabolic diseases in combination
with structural brain malformation-related genes). The sequencing
of genes with limited evidence for gene–disease association, or a
panel comprised of genes with mixed clinical presentations, may
result in confusion regarding the medical interpretation of the
laboratory report and certainty of potential molecular diagnoses.
Methods to assess the pathogenicity of a speciﬁc variant
within an established disease gene have been well described.13
However, standardized guidelines or consistent methodologies
for the assessment of the gene, itself, have been less well studied
and reported in the literature. This pertains directly to clinical
relevance. Currently, there is a recognized need in the medical
and genetics community for improved resources to assess these
disease–gene associations in epilepsy and other diseases.
ClinGen (Clinical Genome Resource) is a National Institutes
of Health-funded resource that sets out to deﬁne, annotate, and
curate the clinical signiﬁcance of reported disease genes.14
Annotation for the genes involved in epilepsy has been initiated
by a ClinGen-based working group15 and is available online
(www.clinicalgenome.org). Other elements of the curated
resource will include the “actionability” of any given disease
gene, as well as the aforementioned variant calls of the known
disease genes in association with ClinVar. The ClinGen database is
dynamic, and it will broaden as additional knowledge is acquired.
The use of a standardized method, such as ClinGen, is tailormade for the Ontario EPI program. Any clinical laboratory offering
genetic testing for epilepsy would be expected to use the methods
outlined by ClinGen to assess the clinical signiﬁcance of genes
offered on a panel (or to use the available information at the
ClinGen website). In addition, the “actionability” of a gene will be
assessed in a consistent manner, and this will highlight the genes
that have a direct impact on management (e.g., ALDH7A1 and
treatment with pyridoxine). This would then be used to inform best
turn-around-times (TATs) for a genetic test result.

ad hoc working groups, and the end users of the panel test, in order
to facilitate this process and ensure that performance outcomes of the
epilepsy panels are captured and reviewed every 1–2 years. Such
measures will include a review of available, epilepsy-related databases and literature to include any genes reported to be associated
with epilepsy and meeting the ClinGen requirements for “Strong” or
“Deﬁnitive” evidence or to exclude any genes based on limited
(or lack of) evidence. Annual reports will include the number of tests
conducted by the clinical laboratory, positive results (diagnostic
yield), negative results, and uncertain results, including the average
number of variants of uncertain signiﬁcance per patient. Other
laboratory indicators, such as TATs, must also be included. These
measures will be reviewed by a Program Advisory Group, which
will be appointed by the MOHLTC for the purpose of evaluating
and monitoring the proposed services, as well as make recommendations for continuous improvement, including any changes to the
genes included on each panel. This group is expected to be
comprised of two to three independent experts in the ﬁeld of clinical
testing.
Lastly, the Ordering Physician will be required to provide the
clinical laboratory with information pertaining to (1) the clinical
interpretation of molecular results for their patient, (2) if there
was any change in management as a result of a positive diagnosis,
or lack of a diagnosis, and (3) if additional tests/consultations
were ordered. This information will be expected to be collected
within 3 months of sending the ﬁnal results report to the Ordering
Physician. This information will be collected and maintained by
the clinical laboratory and be summarized as part of the ongoing
evaluation process. The summary will therefore provide information regarding, among others outcomes, the diagnostic yield
and positive predictive values of the test by panel, gene, and
indication. This will require signiﬁcant resources (e.g., a genetic
counselor and the management of a database).
Clinical Requirements for the Ontario-Based Tests
Pretest Evaluation and Counseling
Individuals must undergo pretest evaluation and counseling for
genetic testing. This may be performed by a genetic counselor,
geneticist, or other clinician with suitable training and knowledge
base (e.g., metabolics specialist, neurologist, pediatrician, or family
doctor) ordering the test. This is an expectation that must be met for
all genetic tests and will be a focus of the genetics portion of the
Project ECHO CME accredited curriculum. The counseling will
include a discussion of the beneﬁts and risks as well as limitations
of genetic testing (false negative) and the high likelihood of
detecting variants of unclear signiﬁcance (VUS) that may require
testing of additional family members, as outlined below, in an
attempt to resolve the variant classiﬁcation.
Clinical algorithms have been summarized in Figures 2 and 3
and Supplementary Appendix 1. These are meant as a guide for
the clinician considering genetic testing.

Recommendation 3: Implement a Robust Evaluative
Programmatic Framework

Post-Test Management Considerations

The broad and uniform implementation of an evidence-based
gene testing program requires a robust framework for ongoing
evaluation. It is expected that the clinical laboratories responsible
for epilepsy panel testing in Ontario will involve an ongoing
consultation process with local experts (clinical and laboratory),

Post-test management considerations are varied and will
depend on the speciﬁc results. These considerations should be
discussed in the pretest counseling phase of testing.
Providers requesting testing are expected to communicate the
results of the genetic test to the patient and family and take
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Figure 2: Suggested Ontario clinical algorithm for generalized and early-onset epilepsy panel testing. This is a guide to aide clinicians for
panel selection. In Ontario, individuals with epilepsy are required to have the appropriate work-up as deﬁned in criteria for panel testing9
(http://www.health.gov.on.ca/en/pro/programs/gtac/). This includes an assessment by a neurologist or epileptologist with appropriate laboratory,
imaging and electroencephalogram (EEG) studies. If the individual is young (<1 year) and does not present with an obvious recognizable syndrome,
consider Panel 3 (Early Infantile Epileptic Encephalopathy Panel). If the patient has multisystem disease, which includes epilepsy, consider whole
exome sequencing (WES). If there is clinical suspicion of an “actionable” gene consider Panel 6 (STAT Option). If the individual is 1–3 years
(approximately), nonsyndromic, with global developmental delay (GDD) or intellectual disability (ID), consider Panel 7 (Comprehensive Panel). If
the individual presents with myoclonic epilepsy, consider Panel 2 and if the seizures present in a previously well child, consider Panel 4 (ChildhoodOnset Epilepsy Panel). If older than 3 years of age and in context of ID/GDD, consider an ID-speciﬁc panel or WES if considered syndromic.

appropriate action depending on the outcome of the results.
A positive result may require referral to another service, further
(invasive and noninvasive) investigations, and for other individuals in the healthcare team to be made aware. A positive result
may also require appropriate medical management and/or surveillance measures to be initiated. Post-test genetic counseling
also needs to be offered, and at-risk family members should
be offered the option of a referral for genetic counseling
(+/− carrier testing) as appropriate.
As mentioned above, classiﬁcation of VUS may require further
evaluation in the context of the patient and family structure. This
may require the testing of relatives, in particular the parents, to
assess de novo status or determine if two variants are in cis
(coupled) or trans (repulsion). A negative result may require
additional testing be performed including a reﬂex to a broader
epilepsy gene panel available by the clinical laboratory or, if
appropriate testing criteria are met, genome-wide sequencing.
Technical Considerations
Required Panel Core Genes
The goal for implementation of Ontario-based epilepsy testing
is to provide panel test(s) that includes genes that meet evidencebased criteria as proposed by ClinGen, or other initiatives, as well
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as provide a comprehensive and beneﬁcial test for individuals
living with epilepsy and the care physicians. An initial “core”
complement of epilepsy gene panels is listed in Supplementary
Appendix 1. The genes listed would be expected to be present on
any proposed panel for testing in Ontario.
The recommended clinical indications for each panel (e.g.,
Focal Epilepsy Panel) are based on commercially available
panels, the literature, and the experience of the EPI Working
Group Technical and Clinical Subgroups. We recognize that
panel composition will change as novel epilepsy genes are
identiﬁed. As such, a testing program that includes an ongoing
reevaluation of gene content and the performance of the respective panels will be an absolute requirement for implementation.
These panels were generated in January of 2018, and the gene
composition of the panels was updated in August of 2019.
The Recommended Gene Panels include: (1) Focal Epilepsy;
(2) Progressive Myoclonic Epilepsy; (3) Early Infantile Epileptic
Encephalopathy; (4) Childhood-Onset Epilepsy; (5) Epilepsy
associated with brain malformations; (6) a “STAT”or “Urgent”
Epilepsy panel; and (7) a Comprehensive Epilepsy Panel. The
speciﬁc genes on these panels are outlined in Supplementary
Appendix 1. In addition, Figures 2 and 3 suggest clinical algorithms to aide clinicians when deciding on the most appropriate
panel. These algorithms are not meant to represent a required
approach but are meant to serve as a guide for panel selection.
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Figure 3: Suggested Ontario clinical algorithm for focal seizures panel testing. This is a guide to aide clinicians
for panel selection. In Ontario, individuals with epilepsy are required to have the appropriate work-up as deﬁned in
criteria for panel testing9 (http://www.health.gov.on.ca/en/pro/programs/gtac/). This includes an assessment by a
neurologist or epileptologist with appropriate laboratory, imaging, and EEG studies. If clinical assessment and
imaging studies show evidence of tuberous sclerosis, consider testing TSC1 and TSC2. If imaging consistent with a
brain malformation consider Panel 5 (Brain Malformation Panel associated with epilepsy) and Panel 1 if EEG
studies shows evidence of focal epileptiform activity but no malformation on imaging studies.

Speciﬁc Technical Considerations
The platform and technical considerations for epilepsy gene
testing in Ontario will include the selection of the NGS
instrument, and the DNA library preparation technical procedures. The laboratory must ensure that the performance of
these two components provides gene testing data quality that is
equivalent to Sanger sequence analysis for single-nucleotide
variants (SNVs), in/dels, and multiplex ligation PCR ampliﬁcation (MLPA) for detection of copy number alterations.
The sequencing instrumentation used should enable quality
and performance standard assessment. A number of speciﬁc
requirements were also deemed to be important by the Technical Group. These include:
1. Coverage for every nucleotide in every coding exon ± 10 bp
of adjacent intronic sequence.
In order to ensure adequate sensitivity and speciﬁcity, the
minimum recommended depth of coverage should be set at a
level that ensures detection of heterozygous SNVs and small
insertions/deletions (in/dels) for all nucleotides in the target region.
A minimum sequencing depth of 20–30× for any single nucleotide
in the target region is recommended for NGS technologies
currently used for diagnostic applications. If this criterion is not
met, the laboratory should also perform Sanger sequencing of the
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region. There may also be regions that are routinely refractory to
NGS (e.g., GC rich regions or long stretches of short repeats). The
regions that have previously been shown to have a signiﬁcant
proportion of pathogenic variants, and do not meet minimum
coverage requirements should undergo Sanger sequencing.
Sanger sequencing may not be possible for certain regions
(i.e., pseudogenic regions), and these need to be deﬁned as part
of the validation and clearly described in the clinical report.
The authors recognize that a minimum 20–30-fold depth
of coverage, per nucleotide is not sufﬁcient to detect copy
number variants.16,17 Should a laboratory opt for, and propose,
an NGS-based assessment of copy number variants (CNVs), the
depth of coverage, at the “exon” level should be a minimum of
200-fold, and a minimum of 50-fold at the “nucleotide” level.16,17
2. Testing for Copy Number Variants (CNVs)
CNVs detectible at least at exon level resolution (the standard
for MLPA) must be performed for the select core genes with CNV
assessment requirement routinely as part of the panel/subpanel
screen (see Core Genes and Panels section in Supplementary
Appendix 1). In addition to the required CNV assessment of these
selected genes, given emerging evidence of pathogenic CNVs
across the genome, routine CNV assessment for all remaining
genes is suggested, but not mandatory. Since targeted MLPA
approaches for routine CNV screening of multiple genes is not
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a feasible and cost effective option, comprehensive approaches are
recommended. These can include, and are not limited to, NGSbased CNV analysis or microarray CNV analysis.
3. Ability to resolve pseudogenic regions
For pseudogenic regions, it can be difﬁcult to determine whether
an identiﬁed variant resides in the pseudogene or the gene targeted
on the panel. For example, SYNGAP1 has a partial pseudogene, and
a long-range PCR approach is required to map CNVs identiﬁed by
NGS. Some such regions may not be resolvable for CNV analysis
without special considerations in the NGS design and custom
analytical procedures. Any such regions must clearly be described,
in detail, or identiﬁed as limitations of the assay in clinical reports
and testing validation documents. This applies to CNVs, SNVs and
in/dels.
4. Technical conﬁrmation of NGS ﬁndings
At the discretion of the laboratory, variants classiﬁed
as American College of Medical Genetics (ACMG) category
“Pathogenic,” “Likely Pathogenic” and “Variants of Uncertain
Signiﬁcance (VUS)” should be conﬁrmed by Sanger sequencing
or other appropriate methodology, when there is signiﬁcant risk
the variant is a false-positive. While the Sanger sequencing of
SNVs is recommended, it would not be considered a mandatory
prerequisite. However, for SNVs that are not conﬁrmed by
Sanger sequencing, we would require the laboratory to provide
evidence for, and a description of, the procedures used to
minimize the laboratories false-positive or false-negative test
rate and procedures to ensure sample identity and integrity
(e.g., the tracking of samples using molecular barcoding). We
would also highly recommend Sanger sequencing of small
insertions and deletions (in/dels) or other complex variants from
the source DNA specimen.
5. Validation should include a range of specimens
The laboratory must demonstrate that variants such as SNVs
and in/dels can be detected with the equivalent accuracy of
previously established methodology (e.g., Sanger sequencing).
While size of the detectable insertions, deletions and in/dels
may vary depending on the sequence context and NGS
technologies, size range validations should aim to include
single to >50 nucleotides variants, and exon/gene deletions and
duplications for CNV analysis.
Since mosaic pathogenic variants have been reported in
epilepsy genes,18 validation of analytical procedures (e.g., a
dilution series) should be designed to ensure detection of
a predeﬁned degree of mosaicism (e.g., 20%) for a limited subset
of genes (see Supplementary Appendix 1).

for persons with epilepsy. Furthermore, the recommended testable epilepsy-related genes are based on an evidence-based
framework (ClinGen), providing meaningful results that are
interpretable by the ordering care providers with reduced risk
of confusion. Lastly, the intent is for a program based on
continuous improvement, current literature, laboratory performance metrics, and clinical outcome data collected from the
ordering physician. This comprehensive programmatic approach
to genetic testing is unique and will provide a robust mechanism
providing high-quality testing.
The proposed epilepsy testing herein is based on a panel
approach. This includes the option of a targeted or comprehensive
panel approach or alternatively a ﬁltered “exome” panel. Broader
whole “exome” approaches to test for rare diseases, which
include those with epilepsy or encephalopathies, are also advocated. Eligible Ontario patients can access exome sequencing if
they meet the ministry’s eligibility criteria for testing, which are
based on the GTAC report, “The Use of Genome-Wide Sequencing for Undiagnosed Rare Genetic Diseases,” to be considered for
testing as an OHIP-funded service (http://www.health.gov.on.ca/
en/pro/programs/gtac/reports.aspx). For those with epilepsy
plus additional comorbidities such as dysmorphic features,
multisystem involvement, or progressive clinical course, an
exome sequencing strategy may be the better initial test.
However, for those with isolated epilepsy (± refractory, ± early
onset) without additional comorbidities, the criteria for exome
sequencing would not be met and a panel-based approach is an
option that offers a comparable diagnostic rate.4
This implementation plan should serve as a helpful guide
for other broad clinical indications being considered for
provincially based patriation of testing, such as ataxia or
neuromuscular disorders. It may also serve as a guide for
other provinces in Canada or countries with a similar healthcare delivery model, wishing to implement an evidence-based
genetic testing program. An evidence-based approach to
diagnostic testing is key to responsible test implementation
and utilization, particularly in a single-payer healthcare system
such as Ontario.
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DISCUSSION
The comprehensive testing strategy summarized in this report
is based on the consensus opinion of a working group of
neurologists, medical geneticists, and laboratory scientists with
expertise in genetic testing and epilepsy genetics. The incorporation of ECHO is unique for a genetic testing program as it
facilitates the education of additional providers throughout
Ontario in order to provide increased access to genetic testing
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